Annovis Bio (ANVS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual Meeting scheduled for June 17, 2026, will be held virtually, allowing stockholders to attend, vote, and submit questions online.
Proxy materials and annual report are available online, with options to request paper or email copies at no charge.
Registration is required by June 16, 2026, to participate in the virtual meeting.
Voting matters and shareholder proposals
Election of five directors: Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of an amendment to the 2019 Equity Incentive Plan.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and proposals 2, 3, and 4, and "2-YEARS" for the frequency of say-on-pay votes.
Latest events from Annovis Bio
- Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026.ANVS
Q2 2026 - Buntanetap shows late-stage efficacy and safety in Alzheimer's and Parkinson's, targeting NDA filings in 2027–2028.ANVS
Investor presentation - Buntanetap delivers cognitive and motor improvements in AD and PD with strong safety and biomarker support.ANVS
Corporate presentation - Q1 net loss rose to $17.6M as R&D spending surged; cash runway extends to Q4 2026.ANVS
Q1 2026 - Annual meeting to vote on directors, auditor, equity plan, executive pay, and ESG priorities.ANVS
Proxy filing - Buntanetap delivers cognitive and motor benefits in AD and PD, with strong safety and market potential.ANVS
Corporate presentation - Buntanetap demonstrates cognitive and motor benefits in late-stage trials for AD and PD.ANVS
Corporate presentation - Pivotal Phase 3 AD trial launched, OLE PD study underway, and cash runway extends into Q3 2026.ANVS
Q4 2025 - Novel Alzheimer's drug shows strong cognitive gains and disease-modifying potential in trials.ANVS
H.C. Wainwright 27th Annual Global Investment Conference